{"id":20850,"date":"2023-10-30T14:29:51","date_gmt":"2023-10-30T13:29:51","guid":{"rendered":"https:\/\/ggba.swiss\/bactheras-visp-plant-aims-to-revolutionize-microbiome-based-treatments\/"},"modified":"2023-10-30T14:33:33","modified_gmt":"2023-10-30T13:33:33","slug":"lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/","title":{"rendered":"L&rsquo;usine de Bacthera \u00e0 Vi\u00e8ge entend r\u00e9volutionner les th\u00e9rapies microbiomiques"},"content":{"rendered":"\n<p><a href=\"https:\/\/www.bacthera.com\/\">Bacthera<\/a>, une Organisation de D\u00e9veloppement et de Fabrication sous Contrat (CDMO) de premier plan, est sp\u00e9cialis\u00e9e dans l&rsquo;avancement des th\u00e9rapies bas\u00e9es sur le microbiome. En mettant l&rsquo;accent sur la production de traitements ciblant le microbiome humain, l&rsquo;entreprise allie expertise et installations modernes pour relever une s\u00e9rie de d\u00e9fis en mati\u00e8re de sant\u00e9, en mettant l&rsquo;accent sur les soins individualis\u00e9s aux patients et sur les solutions innovantes.<\/p>\n\n\n\n<p>Bas\u00e9 \u00e0 Vi\u00e8ge (canton du Valais), le centre d&rsquo;excellence de Bacthera, baptis\u00e9 MC4a, t\u00e9moigne d&rsquo;un engagement historique dans la production de traitements r\u00e9volutionnaires bas\u00e9s sur le microbiome. Parmi ceux-ci, le SER-109, un produit de <a href=\"https:\/\/www.serestherapeutics.com\/\">Seres Therapeutics<\/a>, vise \u00e0 combattre la r\u00e9currence de l&rsquo;infection \u00e0 Clostridioides difficile (rCDI). Cette infection, qui survient g\u00e9n\u00e9ralement \u00e0 la suite d&rsquo;un traitement antibiotique, provoque des diarrh\u00e9es potentiellement mortelles.<\/p>\n\n\n\n<p>Lukas Sch\u00fcpbach, CEO de Bacthera, explique : \u00ab&nbsp;Avec notre nouveau centre d&rsquo;excellence en microbiome \u00e0 Vi\u00e8ge, nous nous r\u00e9jouissons de soutenir la fabrication de th\u00e9rapies \u00e0 base de microbiome qui sauvent des vies, comme le SER-109.&nbsp;\u00bb Eric Shaff, CEO de Seres Therapeutics, s&rsquo;est fait l&rsquo;\u00e9cho de ses sentiments en soulignant l&rsquo;importance du partenariat avec Bacthera pour amplifier la production de SER-109 afin de r\u00e9pondre \u00e0 une demande croissante.<\/p>\n\n\n\n<p>La collaboration entre Bacthera et Seres Therapeutics a d\u00e9but\u00e9 il y a deux ans avec la noble vision de fabriquer le SER-109. Thomas Steinmann, qui supervise le site de Vi\u00e8ge, a r\u00e9sum\u00e9 les progr\u00e8s en cours en indiquant&nbsp;: \u00ab&nbsp;Chaque jour, des machines indispensables \u00e0 la future production commerciale de VOWST\u2122 (spores de microbiote f\u00e9cal, live-brpk) sont mises en service dans les locaux de Bacthera. Notre \u00e9quipe d&rsquo;experts \u00e0 Vi\u00e8ge effectue une transition transparente dans ce nouvel environnement, en se pr\u00e9parant \u00e0 la qualification des performances du processus.&nbsp;\u00bb<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Un p\u00f4le d&rsquo;excellence dans les traitements du microbiome<\/h4>\n\n\n\n<p>Le c\u0153ur de l&rsquo;accord entre Bacthera et Seres Therapeutics est d&rsquo;\u00e9largir les horizons de fabrication commerciale de Seres. Gr\u00e2ce \u00e0 la participation de Bacthera, le SER-109 devrait voir son potentiel de production commerciale augmenter, ce qui en fera peut-\u00eatre le premier produit du domaine de la bioth\u00e9rapie vivante \u00e0 \u00eatre produit commercialement.<\/p>\n\n\n\n<p>Situ\u00e9 dans le parc industriel de Lonza \u00e0 Vi\u00e8ge, le MC4a de Bacthera s&rsquo;\u00e9tend sur une surface de 12&rsquo;000 m\u00e8tres carr\u00e9s. Il abrite trois \u00e9tages de fabrication distincts, dont l&rsquo;un sera exclusivement consacr\u00e9 \u00e0 la production du SER-109. Cette initiative s&rsquo;appuie fortement sur le concept \u00e9prouv\u00e9 de <a href=\"https:\/\/www.lonza.com\/about-us\/our-locations\/visp-switzerland\">Lonza Ibex Solutions<\/a>, garantissant des lancements commerciaux rapides et une production en continu. Jean-Christophe Hyvert, President of Biological Products and Cells &amp; Genes chez Lonza, a comment\u00e9 l&rsquo;importance de cette collaboration : \u00ab&nbsp;Cette collaboration illustre parfaitement l&rsquo;offre de Bacthera en mati\u00e8re de fabrication de LBP comme partenaire strat\u00e9gique pour la commercialisation. Bacthera utilisera une installation bas\u00e9e sur les solutions d&rsquo;Ibex pour offrir flexibilit\u00e9, rapidit\u00e9 et garantie d&rsquo;approvisionnement, ce qui marque un tournant dans la progression des th\u00e9rapies cibl\u00e9es sur les microbiomes.&nbsp;\u00bb<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Vi\u00e8ge, le centre d&rsquo;excellence MC4a de Bacthera se pr\u00e9pare \u00e0 fabriquer des th\u00e9rapies microbiomiques transformatrices, notamment le SER-109 de Seres Therapteutics.<\/p>\n","protected":false},"author":6,"featured_media":20846,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1170,1171,1168],"class_list":["post-20850","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-manufacturing-fr-2","tag-pharma-fr-2","tag-technology-park-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bacthera veut r\u00e9volutionner les th\u00e9rapies microbiomiques \u00e0 Vi\u00e8ge<\/title>\n<meta name=\"description\" content=\"A Vi\u00e8ge, le centre d&#039;excellence MC4a du CDMO Bacthera se pr\u00e9pare \u00e0 fabriquer des th\u00e9rapies microbiomiques transformatrices.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bacthera veut r\u00e9volutionner les th\u00e9rapies microbiomiques \u00e0 Vi\u00e8ge\" \/>\n<meta property=\"og:description\" content=\"A Vi\u00e8ge, le centre d&#039;excellence MC4a du CDMO Bacthera se pr\u00e9pare \u00e0 fabriquer des th\u00e9rapies microbiomiques transformatrices.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-30T13:29:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-30T13:33:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Bacthera_Visp-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"L&rsquo;usine de Bacthera \u00e0 Vi\u00e8ge entend r\u00e9volutionner les th\u00e9rapies microbiomiques\",\"datePublished\":\"2023-10-30T13:29:51+00:00\",\"dateModified\":\"2023-10-30T13:33:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/\"},\"wordCount\":542,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Bacthera_Visp-1180x811-1.jpg\",\"keywords\":[\"Biotech\",\"Manufacturing\",\"Pharma\",\"Technology Park\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/\",\"name\":\"Bacthera veut r\u00e9volutionner les th\u00e9rapies microbiomiques \u00e0 Vi\u00e8ge\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Bacthera_Visp-1180x811-1.jpg\",\"datePublished\":\"2023-10-30T13:29:51+00:00\",\"dateModified\":\"2023-10-30T13:33:33+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"A Vi\u00e8ge, le centre d'excellence MC4a du CDMO Bacthera se pr\u00e9pare \u00e0 fabriquer des th\u00e9rapies microbiomiques transformatrices.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Bacthera_Visp-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Bacthera_Visp-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"Situ\u00e9 dans le parc industriel de Lonza \u00e0 Vi\u00e8ge, le MC4a de Bacthera s'\u00e9tend sur 12'000 m\u00e8tres carr\u00e9s et comprend trois \u00e9tages de fabrication, dont un d\u00e9di\u00e9 \u00e0 la production du SER-109. | \u00a9 Bacthera\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"L&#8217;usine de Bacthera \u00e0 Vi\u00e8ge entend r\u00e9volutionner les th\u00e9rapies microbiomiques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bacthera veut r\u00e9volutionner les th\u00e9rapies microbiomiques \u00e0 Vi\u00e8ge","description":"A Vi\u00e8ge, le centre d'excellence MC4a du CDMO Bacthera se pr\u00e9pare \u00e0 fabriquer des th\u00e9rapies microbiomiques transformatrices.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/","og_locale":"fr_FR","og_type":"article","og_title":"Bacthera veut r\u00e9volutionner les th\u00e9rapies microbiomiques \u00e0 Vi\u00e8ge","og_description":"A Vi\u00e8ge, le centre d'excellence MC4a du CDMO Bacthera se pr\u00e9pare \u00e0 fabriquer des th\u00e9rapies microbiomiques transformatrices.","og_url":"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2023-10-30T13:29:51+00:00","article_modified_time":"2023-10-30T13:33:33+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Bacthera_Visp-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"L&rsquo;usine de Bacthera \u00e0 Vi\u00e8ge entend r\u00e9volutionner les th\u00e9rapies microbiomiques","datePublished":"2023-10-30T13:29:51+00:00","dateModified":"2023-10-30T13:33:33+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/"},"wordCount":542,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Bacthera_Visp-1180x811-1.jpg","keywords":["Biotech","Manufacturing","Pharma","Technology Park"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/","url":"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/","name":"Bacthera veut r\u00e9volutionner les th\u00e9rapies microbiomiques \u00e0 Vi\u00e8ge","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Bacthera_Visp-1180x811-1.jpg","datePublished":"2023-10-30T13:29:51+00:00","dateModified":"2023-10-30T13:33:33+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"A Vi\u00e8ge, le centre d'excellence MC4a du CDMO Bacthera se pr\u00e9pare \u00e0 fabriquer des th\u00e9rapies microbiomiques transformatrices.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Bacthera_Visp-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Bacthera_Visp-1180x811-1.jpg","width":1180,"height":811,"caption":"Situ\u00e9 dans le parc industriel de Lonza \u00e0 Vi\u00e8ge, le MC4a de Bacthera s'\u00e9tend sur 12'000 m\u00e8tres carr\u00e9s et comprend trois \u00e9tages de fabrication, dont un d\u00e9di\u00e9 \u00e0 la production du SER-109. | \u00a9 Bacthera"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/lusine-de-bacthera-a-viege-entend-revolutionner-les-therapies-microbiomiques\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"L&#8217;usine de Bacthera \u00e0 Vi\u00e8ge entend r\u00e9volutionner les th\u00e9rapies microbiomiques"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/20850","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=20850"}],"version-history":[{"count":2,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/20850\/revisions"}],"predecessor-version":[{"id":20854,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/20850\/revisions\/20854"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/20846"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=20850"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=20850"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=20850"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}